Sector News

Roche says will buy U.S. maker of prenatal Down syndrome test

December 2, 2014
Life sciences
(Reuters) – Roche said on Tuesday it will acquire San Jose, CA-based Ariosa Diagnostics, Inc., a molecular diagnostics firm which makes a prenatal test to assess the risk of Down syndrome and other genetic abnormalities.
 
Financial details of the deal were not disclosed.
 
“The acquisition of Ariosa is another example of Roche’s commitment to advanced molecular diagnostics,” Roche diagnostics executive Roland Diggelmann said in a statement.
 
The Basel-based drugmaker said in August it would buy U.S. biotech company InterMune Inc for $8.3 billion in cash, in a move to expand into the treatment of rare or incurable diseases.
 
(Reporting By Katharina Bart; Editing by Maria Sheahan)

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend